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As the Europe of 1993 draws closer, we face a possible delay in the harmonization of the pharmaceu-
ticals market. Significant differences remain in a sector which is important in public health terms 
and of strategic significance for the European economy. 
The welter of proposals for Directives which the EC Commission has only recently adopted bears 
witness to the contrast between the irreversible advance of the European unification process and 
the delay in harmonizing the pharmaceuticals sector. 
The main reasons for the delay are to be found in the resistance occasioned by the radically different 
situations in the individual Member States : Europe's schools of medical thought differ in their 
historical, cultural and therapeutic traditions, and this has led to differing approaches to health 
protection. 
Differences are also created by the tendency of national authorities to introduce legislation which 
paradoxically often treats medicine simply as an economic item which generates expenditure, rather 
than as a vital tool for improving our quality of life. 
The situations pertaining In the individual Member States reflect the prevalence (and alternation) of 
these two approaches. National legislation has thus lacked the continuity and the strategic overview 
needed to give the sector the certainties it requires. 
Public authorities' alternately "permissive" and "repressive" use of their significant powers of control 
has also affected the sector's manufacturing decisions, and the resultant uncertainty has affected 
investment. Scientific research has suffered particularly, and this has had a direct impact on the avail-
ability of effective drugs for new emerging diseases. 
A body of Community legislation that places the interests of the patient at the forefront, though-
without ignoring the public cost aspect, is indeed  needed~ But, we must not underestimate the 
importance of the industrial aspects. 
Community measures are needed to help Europe's pharmaceutical compani~s  to remain competitive, 
especially against their rivals, in the United States and Japan. The emphasis must be on quality, which 
can only be Improved by coordinating and boosting the fundamental role played by scientific research. 
Of particular interest to industry Is the ESC's call for the opening of EC research programmes to in-
company industrial research, which is an important link between the university-research and the final 
application stages. 
In passing judgement on the programme of Directives, one has to weigh the cautious wording of some 
provisions and the weakness of some of the practical indications against the complexities of the 
harmonization process which lies ahead. It must also be remembered that we are not, as in the past, 
dealing solely with general indications, but with key areas of the "pharmaceutical system", so radical 
changes are inevitable. 
The programme put forward by the Commission covers many areas of the drug production and distri-
bution chain. Specific provisions are laid down for wholesale distribution and for package labelling 
and leaflets. Supply of drugs is dealt with in the proposal on "legal status". A later proposal on the 
advertising of medicinal products for human use regulates the advertising of prescription and over-
the-counter drugs to the general public, doctors and health professionals. 
The  proposal to create a supplementary protection certificate for medicinal products aroused 
particular interest in the industry. The proposal addresses the need to improve patent protection, 
currently governed by the European Patents Convention which covers all products. 
The length of  time that a patent remains protected is subject to gradual "erosion", owing to the time 
taken by the ,administrative procedures and the need to check the product's quality, efficacy and 
safety. 
5 The supplementary certificate certifies industrial property ownership and extends the basic patent. 
It is valid for a maximum period of 16 years from the date on which the drug was authorized for 
marketing, and allows an extension of the basic patent for a maximum period of ten years. 
While the Directives listed above will all have a growing influence on the EC pharmaceuticals system, 
the most radical development is the proposal for a Regulation laying down Community procedures 
for the authorization and supervision of medicinal products. 
The proposal concerns the setting-up of an agency which the Commission intends should become 
the real regulator of the EC market. 
In addition to taking over many tasks hitherto carried out by the Member States, the agency is increas-
ingly to play a central role in coordinating and monitoring the quality, efficacy and safety of drugs 
marketed in the Community. 
The proposal is currently the subject of a complex political debate; some circles go so far as to 
question the need for a centralized assessment body. The ESC has adopted an Opinion on the subject, 
for which I was Rapporteur. The Opinion welcomes the proposal and comes out in favour of estab-
lishing a centralized evaluation agency. 
Whilst supporting the general thrust of the proposal, the ESC makes a number of general and specific 
comments. The main points made concern the central role of the Committee for Proprietary Medicinal 
Products (CPMP) within the agency. The ESC proposes that the CPMP be strengthened by a multidis-
ciplinary scientific contribution guaranteeing balanced representation of the various schools of 
medical thought in the Community. 
The Opinion outlines the health protection  and industrial policy tasks which should be assigned to 
the agency. Such a totally new system will have to be phased in over a period whose duration is difficult 
to determine in advance. In order to ensure that the process goes smoothly and to facilitate the 
completion of the new structures, existing instruments should be retained during the transitional 
period until the new EC instruments have got through any teething troubles. 
Harmonization of the authorization procedures has formed the central feature of the debate. 
The ESC considers that continued use of the national procedure is justified, as it offers a guarantee 
for smaller firms producing drugs solely for the domestic market. Moreover,the national procedure 
will form the basis for the decentralized EC procedure. 
The ESC recognizes that the new procedures are made necessary by the failure of the "multi-state" 
procedure, which has been very unevenly applied by the Member States. 
The decentralized procedure is a step forward from the "multi-state" procedure and offers a gradual 
move to the European market for firms which wish to reach this wider market. 
Debate has focused on the centralized procedure, which leads to an authorization immediately valid 
in all Member States. The ESC considers the procedure too restrictive in scope: there are some fields 
of pathology in which there is always a need for effective, highly innovative drugs, and where gradual 
introduction of the centralized procedure would appear warranted. 
For such drugs, the ESC considers that wider use of the centralized procedure would be in the interests 
both of patients and of firms, although it should remain optional. The procedure would have the 
advantage of giving all EC patients immediate access to innovative drugs, while offering firms a 
prestigious label which would help them penetrate markets outside the EC. 
The dual nature of the European pharmaceutical system is evident even from this brief analysis. 
It offers industry a unique opportunity, but it also harbours risks. 
Everything will depend on how well the businesses which have to operate within the new system adapt 
to the new rules and trading conditions. 
6 In the Committee's view, the proposals reflect a cautious gradual, approach which is nevertheless 
ambitious in intention. The innovative features are tempered by a whole host of safeguard clauses 
placed at the disposal of  the Member States. These clauses could seriously encumber the procedures 
and delay real free movement of medicinal products within the Community, which is necessary if 
consumers are to be guaranteed equal access to these products and there is to be equal protection 
of public health and safety. 
The  Committee's recommendations  are  designed  to make the  procedures  more  efficient and 
transparent, taking account of the social aspects of  the pharmaceuticals sector and the need to focus 
on  the interests of the consumer (and  thus the needs of the patient, who should be  the prime 
beneficiary of the drug). 
SERGIO COLOMBO 
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i  • OPINION 
of the Economic and Social Committee 
on the 
Proposal for a Council Directive on the wholesale distribution 
of medicinal products for human use 
(COM (89) 607 final- SYN 229) 
9 On 8 February 1990 the Council decided to consult the Economic and Social Committee, under Article 
100a of the Treaty establishing the European Economic Community, on the 
Proposal for a Council Directive on  the wholesale distribution of medicinal 
products for human use 
(COM(89) 607 final -SYN 229). 
The Section for Industry, Commerce, Crafts and Services, which was responsible for preparing the 
Committee's work on the subject, adopted its Opinion on 6June 1990. The Rapporteur was Mr ROLAO 
GONCALVES. 
At its 278th Plenary Session (meeting of 4 July 1990), the Economic and Social Committee adopted 
unanimously the following Opinion: 
*  *  * 
1.  Introduction 
1.1.  As the link between the manufacturer and the retailer of medicinal products, the wholesaler 
is a key element in the distribution chain of these vital goods. 
1.2.  The wholesaler must provide a swift, efficient and highly economic service, without this 
under any circumstances jeopardizing the quality of the product. 
1.3.  The handling, storage and transport arrangements must ensure that the products are 
distributed where and when required and are of the same quality as they were when they 
left the factory, whether this be inside or outside the Community. 
1.4.  Arrangements are also needed for the withdrawal of products from the market when the 
relevant authorities feel that this must be done in the interests of patient safety. 
1.5.  As a general measure, a code of conduct must be drawn up for wholesalers, modelled on 
those in existence in other areas of the medicinal products sector. This code could either 
be adopted voluntarily by wholesalers or could be based on harmonization laid down by 
the Community in the public interest. The completion of the internal market at the start of 
1993 will increase intra-EC trade, and thus makes action particularly necessary. 
1.6.  The market in medicinal products has various special features: the consumer does not 
generally choose the prescription, and in many cases the product is paid for by a third party. 
These factors work against market transparency, particularly in cases where there is an 
exclusive supplier. Distribution is only one link in the chain from production to consumption, 
and it may be affected by externalities. 
2.  The principles behind the proposal 
2.1.  The proposal forms part of the package of measures contained in the 1985 White Paper for 
completing the internal market. It has three main aims: 
-to  adapt the responsibilities of wholesalers to the new conditions governing cross-frontier 
trade over a wider economic area; 
-to  perfect the arrangements for withdrawing medicinal products efficiently and rapidly 
from the single Community market when necessary; 
-to  step up the fight against counterfeit products, which will become a greater problem 
with the expansion of the market. 
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2.2.  The Commission's proposal, whose objectives cover both economic and safety aspects, 
states that: 
-wholesalers must be registered, and must adhere to certain administrative requirements; 
-wholesalers must follow certain rules in  their work and  must have suitable storage 
premises manned by qualified staff; 
-wholesalers must keep detailed records of their transactions and stocks, conduct checks 
on these records and make them available to the competent authorities. 
2.3.  Whilst taking account of national public health laws and certain specific circumstances 
within Member States, the proposal aims to harmonize the present systems so that they 
can operate within a frontier-free market. 
3.  General Comments 
3.1.  The Committee endorses the aims of the Commission proposal, subject to the following 
comments. 
3.2.  The economies of scale brought by the internal market should cut costs. If there is free 
competition, this must ultimately lead  to a drop in  consumer prices. The  Committee 
considers it essential not to jeopardize this goal with red  tape which would generate 
additional structural expenditure, affecting costs and thus limiting the scope for reducing 
retail prices. Steps will also have to be taken to counter any developments which could 
threaten the transparency of the market. 
3.3.  The  desire  to speed  up  stock rotation  - dictated  by  the  need  to  improve  financial 
management- has been the reason for the rapid computerization of the wholesale sector. 
However, lack of information and finance means that computerization is not yet widespread, 
particularly among smaller firms in the most disadvantaged Member States. The Committee 
asks for this to be borne in mind. It must also be ensured that the new administrative rules 
(especially the keeping of records) are phased in gradually, with the backing of financial 
programmes (TEDIS). 
3.4.  The Committee is concerned about a confluence of activities in certain Member States, in 
the form of either upstream expansion by the retail trade or downstream expansion by 
wholesalers. This is likely to reduce the transparency of the marketing chain and limit the 
free competition which is necessary at each stage, to the detriment of the consumer or of 
whoever is paying for the products. 
3.5.  Rules on  wholesale distribution should not threaten imports and exports from/to third 
countries when these can help satisfy personal health needs and lessen price differences 
between regions. Experience has shown that third-country trade can be reconciled with the 
higher quality standards demanded of medicinal products. 
3.6.  Community legislation on medicinal products should remain flexible, by adapting to socio-
economic trends and taking account of traditional habits in the Member States whilst not 
forgetting the general principles of free competition and the elimination of monopolies. 
3.7.  The Committee draws the Commission's attention to the need for Member States to set 
up monitoring mechanisms to ensure that procedures are followed uniformly throughout 
the Community, in order to prevent discrepancies which could give rise to unfair competition. 
3.8.  The Committee recognizes the seriousness of the problems referred to by the Commission 
with regard to the need to withdraw faulty or counterfeit medicines from the market. It 
therefore calls for public programmes involving all interested parties, from manufacturers 
to consumers, with support from the relevant national and Community authorities. 4.  Specific comments 
4.1.  Preamble 
The Committee suggests that the Commission include a recital highlighting the abiding 
concern of Community pharmaceutical legislation to accord priority to the achievement 
of a high level of protection, in line with Article 100a(3) of the Treaty. 
4.2.  Article 1  (2) 
The  Committee considers that the definition of "wholesale distribution of medicinal 
products" is incomplete and could generate confusion, particularly as the proposal takes 
the form of a Directive which Member States will have to translate into national law. At the 
very least, the text should be made more precise by amending "all activities" to read "all 
commercial activities" and adding "to any bodies other than the final consumer" after 
"supplying". 
4.3.  Article 3 
The end of Article 3(1) should be amended to read"  ... medicinal products for human use". 
The C9mmittee suggests the addition of the following new points: 
"8. Branches of  authorized wholesalers shall be required to meet the conditions laid down 
in Article 5 as if they were independent establishments. 
9.  Manufacturers  who  supply retailers  directly  with  products  not manufactured by 
themselves shall be required to meet the same conditions as wholesalers." 
4.4.  Article 4 
A new Article 4(2) should be inserted, to read as follows: 
"2. Failure to take a decision within the period referred to in Article 4(1) shall for all legal 
purposes be interpreted as signifying the provisional granting of  the authorization referred 
to in Article 3(1)." 
It would also be advisable to adopt similar provisions in the Member States of manufacture 
and distribution. 
The existing Article 4(2) would then become Article 4(3). 
4.5.  Article 5 
To  avoid  serious distortions of competition, the Committee considers it vital that the 
requirements for obtaining authorization should be specified more clearly, with a view to 
closer harmonization between Member States. The Committee therefore proposes: 
-in  point (a), the addition of the following:"  ... , and appropriate procedures to ensure that 
they are handled and transported correctly;" 
-in  point (b), the addition of the following: "qualified personnel who have had appropriate 
technical training and meet ... ;" 
-the addition of the following new points d, e, f and g: 
"d) they must  have appropriate repackaging facilities, as required for  holders of  a manufac-
turing authorization (Article 16 of  Directive 751319/EEC); 
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e) they must have appropriate facilities for the storage of dangerous and inflammable 
products; 
f) they must  have appropriate facilities and  equipment for the storage of  medicinal products 
which have to be stored at a particular temperature; 
g) they must have a sufficient stock of  the medicinal  products habitually  prescribed in the 
area they serve. " 
4.6.  Article 6(b) 
The Committee is surprised that there is no mention of any authorization for wholesalers 
to obtain supplies from manufacturers. It therefore recommends that "who are themselves 
in possession of the authorization" be amended to read: "who are in possession either of 
a manufacturing authorization or the authorization ... ". 
4.7.  Article 6 (e) 
The words "no minimo" ("at least") in the Portuguese version of the first sentence should 
be deleted. (Translator's note: the English version of the Commission document omits this 
phrase.) Inclusion of the phrase "at least" brings a danger that stiffer conditions could be 
set, and this would distort competition between Member States. 
The Committee also questions the feasibility and point of referring to the production batch 
number "for each transaction ...  received or dispatched" except when  "the delivery is 
destined for a retailer". 
4.8.  Article 9 
The Committee proposes that the text of this Article be transferred to a new Article 8(3). 
4.9.  Article 10 
The Committee thinks that the qualifying phrases ("if appropriate" ... "in that case") should 
be deleted, and that the Commission should take a firmer and more concrete stance. At 
all events, the Committee should be consulted on any such proposal. 
Done at Brussels, 4 July 1990. 
The Chairman 
of the Economic and 
Social Committee 
Alberto MASPRONE 
The Secretary-General 
of the Economic and 
Social Committee 
Jacques MOREAU OPINION 
of the Economic and Social Committee 
on the 
Proposal for a Council Directive concerning the legal status 
for the supply of medicinal products for human use 
(COM(89) 607 final • SYN 230) 
15 On 8 February 1990 the Council decided to consult the Economic and Social Committee, under Article 
100a of the Treaty establishing the European Economic Community, on the 
Proposal for a Council Directive concerning the legal status for the supply of 
medicinal products for human use 
(COM(89) 607 final - SYN 230). 
The Section for Protection of the Environment, Public Health and Consumer Affairs, which was 
responsible for preparing the Committee's work on the subject, adopted its Opinion on 5 June 1990. 
The Rapporteur was Mr COLOMBO. 
At its 278th Plenary Session (meeting of 4 July 1990) the Economic and Social Committee adopted 
the following Opinion by 96 votes to 12, with 9 abstentions: 
16 
*  *  * 
1.  Introduction 
1.1.  The Committee notes that the Commission has drafted a proposal which takes as its base 
"a high level  of protection ...  concerning health, safety, environmental protection and 
consumer protection" as envisaged in Article 100a(3) of the Treaty. 
1.2.  The  present  proposal  establishing  harmonized  conditions for the  issue of medicinal 
products to patients is without doubt a further step towards the completion of the internal 
market. 
The  proposal  is designed to eliminate differences in  Member States'  legislation and 
implementing criteria for the supply of medicinal products to patients, and, in particular, 
medicines not subject to medical prescription. It does not cover matters relating to who 
exactly is authorized to prescribe or distribute medicines. 
Here the Committee suggests the insertion in the preamble of a new recital to read as 
follows: 
"Whereas the protection of  public health requires that the dispensing of  medicinal  products 
should always be  supervised by  a professionally  and  legally qualified health specialist, given 
the potential risks of these products' indiscriminate use;" 
1.3.  The Commission sets two basic preconditions for allowing a medicinal product to be sold 
over the counter (OTC): 
- it is safe to use because its effects and toxicity are well known; 
- it is used to treat minor ailments which are easily identifiable by the user and do not justify 
a medical consultation. 
1.4.  Article 4 of the proposal lays down the cases where a prescription must be supplied, listing 
eight possible risk factors which make medical control necessary. 
1.5.  Among these, the risk factor "novelty of the active principle" (also mentioned in Article 3(2)) 
is of particular importance. It is rightly felt that a new chemical substance should not be 
supplied without prescription until adequate information about it is available. 
1.6.  Article 2 of the proposal divides prescription drugs into four categories. For category a) 
products, the prescription may be renewed during a limited period; for category b) products, 
the prescription may not be renewed; and category c) covers products on special prescription 
(containing a psychotropic or narcotic substance). 1.7.  Category d) covers products on restricted prescription, reserved for use in hospitals or by 
certain specialists. 
Several Member States already use this category, as the administration of complex or high-
risk drugs calls for specific controls by specialist bodies. 
2.  General comments 
2.1.  On the relevant categories of medicinal products, the Committee would make the following 
comments: 
2.2.  Some parts of Article 4, which deals with prescription drugs, may prove difficult to interpret, 
and could be interpreted differently by individual Member States. This would be at odds with 
the aims of the Directive, which seeks to group products together uniformly. 
2.3.  The Committee considers that OTC medicinal products perform a practical social function. 
This being the case, the formulation of a single EC-wide criterion for defining OTC medicines 
is to be welcomed. 
2.4.  The  Committee is concerned  at the frequent  references to decisions to be  taken  by 
"competent  authorities"  at  Community  level,  when  there  is  no  definition  of  these 
authorities(1>. 
2.5.  In conclusion, the structure of the Directive can be endorsed as providing useful clarification 
for national authorities which authorize drugs for marketing. 
2.6.  However, the Committee stresses the need for close links between the Directives concerning 
medicinal products currently under preparation and,  more particularly, with the other 
Directives scheduled in the Commission's 1990 work programme. 
3.  Comments on the individual Articles 
3.1.  Article 1(2) 
The differing situations in the Member States as regards the right to prescribe medicinal 
products could create problems here. The Committee therefore asks that efforts be made 
with reasonable speed as warranted by the present situation, to clarify and harmonize such 
rights. 
The Committee also proposes the addition of a third indent, to read as follows: 
"-'Pharmaceutical activity': any act of  dispensing medicinal products, in accordance with 
the requirements of the legislation of  each Member State." 
3.2.  Article 2 
Article 2(a) and (b) 
While endorsing the aims of this Article, the Committee feels that the formula proposed 
by the Commission could prove difficult to implement in practice. A simpler so  Iuton might 
be to merge paragraphs (a) and (b), and make a more clear-cut division between renewable 
and non-renewable prescriptions. 
However, such a solution is complicated by the existence of the Council of Europe lists. 
(1)  The nature and scope of the competent institutional body have still to be determined at Community level. 
17 Article 2(c) 
Replace "medicinal products on special prescription" by "medicinal products containing 
a quantity exceeding a specific level of a substance classified as a psychotropic .... ". 
3.3.  Article 3 
Article 3(2) 
A  clear scientific definition must be  given  of the term  "new chemical  entity", to be 
understood as a new chemical and/or biological entity. 
Article 3(3) 
The annual list should highlight any medicines being transferred from one category to 
another. 
A further point should be added to this Article, to read as follows: 
"5)  Should the legal status for the supply of  a medicine be determined or  altered indepen-
dently of the  marketing authorization procedure or Its renewal every five  years,  the 
competent authorities in the Member States shall substantiate and  publish decisions taken 
on the basis of  Article  2 or  the present Article. Procedures for  appeal against such decisions 
shall be established and brought to the attention of  the persons authorized to market the 
product." 
This procedure is designed to ensure the fullest possible information and prior consultation 
among the organizations representing the various interests concerned, thereby guaran-
teeing that it is based on sound scientific premises and takes account of prevailing social 
conditions. 
3.4.  Article 4 
Article 4(1) 
The term "indirect risk" to human health needs further clarification. Moreover, the criteria 
need to be spelt out in more detail to stop Member States interpreting the words "safety 
in use" differently (as they do at present). 
Article 4(1)(a) 
The term "preclinical" should be deleted as it is impossible at that stage to determine the 
risks to human health. 
Article 4(2) 
In order to put the two categories of medicines on a more equal footing, the Committee 
suggests that Article 4(2) form a separate Article: 
"Article 5 - Medicinal products which ... a medicinal consultation." 
The remaining Articles should be renumbered accordingly. 
Done at Brussels, 4 July 1990. 
The Chairman 
of the Economic and 
Social Committee 
Alberto MASPRON E 
The Secretary-General 
of the Economic and 
Social Committee 
Jacques MOREAU 
N.B.: Appendices overleaf. 
18 APPENDIX  I 
to the Opinion of the Economic and Social Committee 
The following amendments were rejected during the debates, but received at least 25°/o of 
the votes cast. 
Point 1.2. · Third paragraph 
Delete from "Here the Committee ... " to the end of the suggested recital. 
Voting 
For: 28 
Against: 78 
Abstentions: 8 
Point 3.1. Article 1(2) 
Delete the second paragraph: "The Committee ... of each Member State". 
Voting 
For: 28 
Against: 73 
Abstentions: 14 
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APPENDIX  II 
to the Opinion of the Economic and Social Committee 
The following members, present or represented, voted in favour of the Opinion. 
Mr/Mrs/Miss 
ALEXOPOULOS 
ARENA 
ARETS 
ATAIDE FERREIRA 
BAG LlANO 
BERGER 
BERNASCONI 
BERNS 
BERTON 
BLESER 
BODDY 
BOISSEREE 
BORDES-PAGES 
BOS 
BRED I  MA-SAVOPOULOU 
BROICHER 
Vasco CAL 
CAL  VET CHAMBON 
CHRISTIE 
COL  LAS 
COLOMBO 
CALVES CONDE 
CORELL AYORA 
CORTOIS 
COYLE 
van DAM 
DECAILLON 
DELLA CROCE 
VAN DIJK 
DOSSANTOS 
ELSTNER 
ETTY 
EULEN 
FORGAS 
FRANDI 
GARDNER 
GAYETOT 
GREDAL 
GREEN 
HAAS 
HAGEN 
HILKENS 
HOUTHUYS 
JASCHICK 
JENKINS 
JESUS SEQUEIRA 
KAARIS 
KENNA 
KIRCHFELD 
de KNEGT 
KROGER 
LAPP  AS 
LARSEN 
LIVERANI 
LOW 
LUCHETII 
MACHADO VON TSCHUSI 
MADDOCKS 
MAINETII 
MANTOVANI 
MARGOT 
MATIEOLI 
MAY  A  YO BELLO 
MEYER HORN 
MORSELLI 
MOURGUES 
NIELSEN P. 
NIERHAUS 
NOORDWAL 
de NORMANN 
PARDON 
PEARSON 
PELLETIER R. 
PERRIN-PELLETIER 
PETERSEN 
PROUMENS 
QUEVEDO ROJO 
RANGON I-MACHIAVELLI 
RIBIERE 
ROBINSON 
ROL4\0 GONCALVES 
ROUZIER 
SALMON 
SANTILLAN CABEZA 
SCHADE-POULSEN 
SCHNITKER 
SCHOEPGES 
SCHWEITZER 
SMITH A.A. 
SMITH L.J. 
TELLES 
TIEMANN 
TIXIER 
TUKKER 
VIDAL 
YVERNEAU The following members, present or represented, voted against the Opinion. 
Mr/Mrs/Miss 
ASPINALL 
BEALE 
BENTO GONCALVES 
FLUM 
FRESI 
LUSTENHOUWER 
MORELAND 
MUHR 
STORIE-PUGH 
STRAUSS 
TAM LIN 
WILLIAMS 
The following members, present or represented, abstained: 
Mr/Mrs/Miss 
CAMPBELL 
CEYRAC 
DODD 
van EEKERT 
HOVGAARDJAKOBSEN 
NIEUWENHUIZE 
PETROPOULOS 
VANDEN BROUCKE 
WAGNER 
21 OPINION 
of the Economic and Social Committee 
on the 
Proposal for a Council Directive on the labelling of medicinal products 
for human use and on package leaflets 
(COM(89) 607 final • SYN 231) 
23 On 8 February 1990 the Council decided to consult the Economic and Social Committee, under Article 
100A of the Treaty establishing the European Economic Community, on the 
Proposal for a Council Directive on the labelling of  medicinal  products for human 
use and on package leaflets 
(COM(89) 607 final- SYN 231). 
The Section for Protection of the Environment, Public Health and Consumer Affairs, which was 
responsible for preparing the Committee's work on the subject, adopted its Opinion on 5 June 1990. 
The Rapporteur was Mr HILKENS. 
At its 278th Plenary Session (meeting of 4 July 1990) the Economic and Social Committee adopted 
the following Opinion by a majority vote, with ten abstentions: 
*  *  * 
The Committee approves the Draft Directive subject to the following comments. 
1.  Introduction 
1.1.  It should be pointed out that the Commission's proposal to provide the consumer with more 
complete and comprehensible information by means of labelling and leaflets is required 
by Article 100A(3), which states that "The Commission in its proposals ... concerning health, 
safety, environmental protection and consumer protection, will take as a base a high level 
of protection." The Committee is pleased to note that the Commission studied this question 
when drafting its proposal. 
1.2.  The Committee notes that the Commission proposal is to be seen in the context of the 
completion of the Internal Market. For both public health and economic reasons a higher 
degree of regulation is undoubtedly required in the medicinal products market than in many 
other sectors of the economy. This applies particularly to information for patients with 
regard to pharmaceutical products. 
1.3.  The Commission proposal follows on from Directives 65/65/EEC and 75/319/EEC and the 
amendments thereto in Directive 89/341/EEC which regulate respectively labelling and the 
information which  leaflets must contain. The  proposed  Directive  lays  down  detailed 
requirements for labelling and package leaflets. 
1.4.  Generally speaking it should be pointed out that this approach is also consistent with new 
social trends regarding the provision of information. As far as medicines are concerned, 
this means that in a modern society an ever increasing number of people insist on being 
informed in readily understandable language of the effects, advantages and disadvantages 
of medicines. 
1.5.  The Committee notes that the Commission's Draft Directive was drawn up after intensive 
consultations with all interested parties, including consumers. In view of the preceding 
comments (Points 1.1. and 1.4.) the Committee urges the Commission to extend the dialogue 
initiated here in the field of medicinal products to other regulations and not to forget the 
consumer's role in this process. 
In this connection the Committee would refer to the Commission proposal still being drawn 
up on the information to be supplied to doctors, pharmacists and other medical experts. 
25 2.  General comments 
2.1.  With regard to patient leaflets, the Committee would refer to its Opinion of 2 June 1988(1) 
in which it urged the Commission to hold consultations with the consumer organizations 
with a view to establishing adequate rules on the content and form of patient leaflets. 
The Committee is pleased that so many of the points on which consensus was achieved 
in the course of those consultations are to be found in the proposed Directive (Art. 8). The 
Committee urges the Commission to incorporate the remaining points in Article 8, i.e. the 
points with regard to the legal status and the pharmacology of the medicinal product. 
2.2.  The Committee wonders whether the Commission's aims would not be served by laying 
down guidelines for the wording of leaflets for which the manufacturer is responsible. This 
would have a twofold purpose: 
a) to make the job easier for those responsible for writing package leaflets; 
b) to make the presentation of leaflets more uniform. 
The Committee points out that some Member States already apply such guidelines. 
In the Committee's view the guidelines referred to in Article 13 of the proposed Directive 
are too narrow and should be widened to cover all aspects of patient leaflets. 
2.3.  The Committee would even go one step further and urge that, with a view to ensuring that 
product information corresponds as closely as possible to the actual needs of patients, 
manufacturers of identical products listed in  the official monograph of the  European 
Pharmacopoeia be required to use a standard leaflet, since the active ingredients in the 
products are the same and have virtually the same bioavailability. 
2.4.  The Committee urges the Commission to ensure that representatives of consumers and 
all other interested parties are involved in the drafting of guidelines for patient leaflets. In 
addition, it must be possible to take action if, after evaluation, a patient leaflet appears to 
be unsatisfactory. 
3.  Specific comments 
3.1.  Article 3 
3.1.1.  Sub-paragraph (d) 
The Committee would like to see the Commission append to the Directive, besides the 
excipients, a list of E-N umber substances, including and highlighting those which induce 
hypersensitivity  reactions.  These  hypersensitivity  reactions  must  be  confirmed  by 
independent scientific evidence. 
3.1.2.  The Committee urges the Commission to examine the feasibility of using pictograms as 
a means of informing patients. Such  a method  could  be  considered  in  particular for 
psychotropics and narcotics as defined in the UN Convention. EC pictograms for potentially 
dangerous dependency-producing psychotropics and narcotics should be made mandatory 
for the whole Community. The use of different colours for different doses of the same 
product is recommended. Finally, the normal side-effects of medicines must be mentioned, 
along with any special warnings about driving. 
(1)  OJ  No C 208 of 8 August 1988 
26 3.2.  Article 4 
3.2.1.  Paragraph 1, 2nd indent 
The English version should read "quantity of active ingredients" instead of "quantity of 
active constituents". 
3.2.2.  Paragraph 2 
The Committee feels that, both in order to prevent this exception finding ever broader 
application and in view of the need to provide basic information on small packages, the 
common name of the product, the quantities of active ingredients and the batch number 
should appear on the product packaging. 
3.3.  Article 6 
3.3.1.  Paragraph 2 
The Committee approves the provisions set out in Article 6(2) regarding price labelling, 
reimbursement and legal status. The Committee urges the Commission to include in the 
Directive  an  obligation  on  the  part  of  chemists  to  have  information  available  on 
arrangements concerning reimbursement and prices. 
3.4.  Article 8 
3.4.1.  Paragraph 1  a) · third indent 
This indent should be reworded as follows: 
"·pharmaco-therapeutic group, if  there exists a term easily  comprehensible for the patient, 
supplemented by 'OR FAILING THIS THE THERAPEUTIC CHARACTERISTICS'." 
3.4.2.  Paragraph 1  b) 
Insert after "the therapeutic indications": "the pharmacological properties". 
3.4.3.  Paragraph 1  d) 
It is pointed out that antidotes do not exist for all medicinal products. Furthermore, in the 
case of overdoses antidotes may be administered only under medical supervision. 
3.4.4.  Paragraph 1  e) 
Patients should be invited to communicate any undesirable effect not only of new medicinal 
products but of all medicinal products to their doctor or pharmacist. 
3.4.5.  Paragraph 2 
The Committee would point out that in its Opinion of 2 June 1988(2) it stated that: 
"it is vital that the leaflet provide the patient with all  necessary information on the medicine. 
While every effort should be made to avoid alarming the patient, this must clearly not be 
at the expense of the clarity and completeness of the information." 
3.4.6.  Paragraph 3 
Regarding pictograms, see the comments under 3.1.2. 
(2)  OJ  No. C 208 of 8 August 1988 
27 3.5.  Article 12 
3.5.1.  Paragraph 1 
28 
The correct application of this Directive is of considerable importance for public health; 
hence the Committee feels that the imposition of adequate penalties, both general and 
financial, by the competent authorities of a Member State should be made mandatory where 
the provisions of this Directive are not observed. 
3.6.  Article 13 
See Point 2.2. which urges that the guidelines be widened. They should also be mandatory. 
Done at Brussels 4 July 1990. 
The Chairman 
of the Economic and 
Social Committee 
Alberto MASPRONE 
The Secretary-General 
of the Economic and 
Social Committee 
Jacques MOREAU OPINION 
of the 
Economic and Social Committee 
on the 
Proposal for a Council Directive 
on advertising of medicinal products for human use 
(COM(90) 212 final- SYN 273) 
29 On 21 June 1990 the Council decided to consult the Economic and Social Committee, under Article 
100a of the Treaty establishing the European Economic Community, on the 
Proposal for  a Council Directive on advertising of  medicinal  products for  human 
use 
(COM(90) 212 final- SYN 273). 
The Section for Protection of the Environment, Public Health and Consumer Affairs, which was 
responsible for preparing the Committee's work on the subject, adopted its Opinion on 4 December 
1990. The Rapporteur was Mr COLOMBO. 
At its 282nd Plenary Session (meeting of 19 December 1990), the Economic and Social Committee 
adopted the following Opinion with no dissenting votes and one abstention: 
*  *  * 
1.  Preliminary comments 
1.1.  The  proposal  represents  a further  step  in  the  Commission's  drive  to  harmonize  the 
pharmaceutical sector and eliminate barriers to the free movement of medicinal products 
in the run-up to an internal market, ensuring a high level of protection of public health. 
1.2.  The  proposal  forms  part  of the  programme  announced  in  the  1985  White  Paper  on 
completing the  internal  market.  It follows the proposals (discussed  in  the  respective 
Committee Opinions1 on: 
-wholesale distribution of medicinal products for human use; 
- legal status for the supply of medicinal products for human use; 
-labelling and package leaflets of medicinal products for human use. 
1.3.  The proposal seeks to harmonize the rules on  advertising of medicinal products to the 
general public, doctors, and health professionals. 
1.4.  This is an important matter- the pharmaceutical industry spends considerable sums on 
advertising  to the  general  public,  promotion  to  health  professionals  and  medicinal 
information. 
1.5.  The  products of this sensitive sector are  designed to improve human  health and  it is 
reasonable to introduce Community legislation, without prejudice to the general rules laid 
down  in  Directive  8414501EEC  on  misleading  advertising  and  Directive 8915521EEC  on 
television broadcasting. 
1.6.  All Member States have specific legislation on pharmaceutical advertising. 
1.7.  Analysis of the situation in the Member States shows significant points of convergence, 
but  also discrepancies as  regards  both  authorization  and  the  systems and  levels of 
advertising control. Community harmonization is thus needed. 
1.8.  Member States' legislation on the information provided to health professionals presents 
fewer divergencies. This is partly because of the existence of deontological codes of conduct 
at both national and  EC level, which can provide a useful point of reference. 
OJ  No. C 225 of 10 September 1990. 
31 2.  General Comments 
2.1.  The Committee endorses the need for and structure of the proposed Directive, subject to 
the comments and recommendations which follow. 
2.2.  Advertising to the public and to health professionals is treated separately because different 
messages are being conveyed and because current legislation in the two areas differs. While 
it is common practice in  the Member States to include the two areas in  a single legal 
instrument, the Committee is concerned that failure to draw a precise distinction between 
advertising to the public and information/promotion to health professionals could give rise 
to ambiguities. 
2.3.  The  ban  on  public advertising of prescription drugs deserves particular endorsement. 
However, the Committee notes the concern expressed in its Opinion on  legal status of 
medicines, as regards the latitude allowed the Member States in  the classification of 
prescription and OTC drugs. Differing interpretations of the classification criteria would 
have an effect on the authorization of advertising to the public. 
2.4.  The Committee notes the importance of proper health education in order to ensure the 
"rational use" of medicinal products which advertising is supposed to encourage under 
the terms of Article 2(3) of the present proposal. 
2.5.  Although advertising can be an information vehicle, it is not the main one. In no way can 
it replace the information on the product's labelling and in the package leaflet, nor that 
provided by health professionals. 
2.6.  Lastly, the Committee asks the Commission to examine possible ways and fora for achieving 
closer  harmonization  of the  instruments and  bodies  responsible  for  pharmaceutical 
advertising. 
3.  Specific comments 
3.1.  Definitions· Article 1(3) 
3.1.1.  The definition of advertising in Article 1(3) includes information and promotion for health 
professionals. There is a danger here of confusing proper scientific information activity with 
improper incentives to prescribe a particular drug. 
3.1.2.  For example, it has to be determined whether attendance at congresses is a form of illicit 
pressure, or whether these provide an updating necessary for the doctor's further training 
and are potentially in the patient's interest. 
3.1.3.  The vague reference to "invitations ... to congresses" in the third indent of Article 1(3) should 
therefore be deleted, as it seems to imply that any information or training initiatives aimed 
at health professionals are a form of commercial incitement. 
3.2.  Article 2(3) 
The  term  "rational  use"  seems  rather  vague.  The  Committee  suggests the wording 
"appropriate correct use". 
3.3.  Article 4 
3.3.1.  In  the interests of improved consumer protection, the Committee is concerned at the 
alternative offered in the second indent, between (a) inclusion of !!the information necessary 
for correct  usage of the medicinal  product,  such  as  indications for use and  special 
precautions" and (b) a mere "invitation to read the package leaflet carefully". 
32 3.3.2.  The package leaflet is of the utmost importance if the consumer is to be fully informed. 
Advertisements should always include a reminder to read the leaflet. However, it will only 
be read after the medicine has been purchased; patients could make the wrong purchase 
if no explicit counter-indications are provided. 
3.3.3.  Lack of space is no excuse for not providing vital information in a clear and legible form, 
even if it is not advisable to include a welter of technical and scientific details in advertising 
targetted to the general public. 
3.3.4.  However, where the vital information is available on the outer pack, the Committee accepts 
that, in the case of medicines for which no special precautions are necessary a message 
to read the label and or the package leaflet is the best alternative means. 
3.4.  Article 5(d) 
Drug  advertising directed at children should be  banned outright. The words "solely or 
mainly" could offer a loophole for getting round this ban. 
3.5.  Chapter Ill -Wording of the title 
The term "advertising" is an oversimplification for describing the complex promotional and 
information activity aimed at health professionals. The title should include a reference to 
information activity. 
3.6.  Article 3(2) 
This Article should specify that the list of prohibited therapeutic indications is indicative 
and not exhaustive. 
3.7.  Article 8(1) 
3.7.1.  Although it is not possible to give a full definition of a "medical sales representative" in 
a Directive on drug advertising, the fact remains that the definition given is very vague ("shall 
be given adequate training and shall have sufficient scientific knowledge") considering the 
responsibilities which these representatives have. 
3.7.2.  Provision should be made to ensure that representatives have had higher education and 
special training and refresher courses from the company, the health authorities or univer-
sities on the scientific, legal and deontological aspects of the profession. The position of 
the medical sales representative within the pharmaceutical business also requires clarifi-
cation. 
3.7.3.  These points are important because representatives are required to provide information on 
the products and promptly report any side effects. 
3.8.  Article 8(3) 
3.8.1.  It should be specified that the feedback to the company provided by the medical sales 
representative is not the same as the fourth stage of clinical trials and is subject to different 
regulations. The information covered by the present Article is provided free of charge by 
the doctor during normal talks with the sales representative. 
3.8.2.  Moreover, neither this feedback nor stage four can replace a general drug monitoring service 
as envisaged by the WHO. 
33 3.9.  Article 9 
3.9.1.  Clarification  is  needed  of the term  "insignificant  intrinsic value"  in  Article  9(1)  The 
Committee suggests the following wording: 
"objects whose value is not sufficient to induce the health professional to prescribe the 
drug other than in accordance with good clinical practice." 
3.9.2.  If the reference to congresses in Article 1(3) (definitions) is not deleted, the Committee 
proposes that a clause be inserted in Article 9 to exclude from the ban refresher conferences 
held solely to inform and train health professionals. The pharmaceutical industry's work 
in this area should not be discouraged. 
3.1 0.  Article 10 
3.10.1.  The maximum of two free samples (obviously per product) per year seems very rigid. It 
appears to conflict with the need for doctors to familiarize themselves with new drugs and 
learn to use them better. Furthermore, Article 10(b) requires the doctor to make a written 
request for the samples, thus assuming direct responsibility for them. The doctor should 
be given a wider margin of discretion. 
3.10.2.  The list of products of which samples may not be provided should include thermolabile or 
otherwise easily perishable products. Representatives do not have proper premises or 
facilities for storing samples correctly - and these samples are fully-fledged medicinal 
products. 
3.11.  Article 11 
3.11.1.  The proposal should identify the body which is to monitor advertising and the relation 
between image and content of the message, particularly where this exceeds the bounds 
of proper information and constitutes an  incentive to use a particular drug. 
3.11.2.  It is necessary to harmonize the monitoring systems of the Member States, which range 
from specific authorization bodies to self-policing arrangements. The free movement which 
will soon be achieved by the Single Market makes Commission consideration of this point 
particularly important. 
3.11.3.  The moves to draw up a European Code of Practice in this sector are to be welcomed. The 
European pharmaceutical industry has so far only drawn up a code for drugs promotion 
to health professionals, and this does not lay down sufficient implementing guarantees. 
3.11.4.  The Committee asks the Commission to investigate possible ways and fora for dealing with 
this matter at Community level. 
3.12.  Article 12 
The in-company scientific service must be headed by a health specialist offering a maximum 
guarantee of professional skills and legal responsibility. The existence of such a service 
does not of course preclude the existence of (or indeed, the need for) other information 
channels for health professionals, such as national or European-level data banks. 
3.13.  Article 13 
3.13.1.  Further consideration is needed of the clause (Article 13(1)) allowing marketing authori-
zations to be suspended if the Directive is not observed. 
34 3.13.2.  If drugs of proven therapeutic value and novelty had to be withdrawn, this would unfairly 
deprive patients of a vital drug. 
3.13.3.  It seems right to impose financial and  legal penalties if a company commits a serious 
offence. 
3.13.4.  However, the punishment should be in keeping with the severity of the risks engendered 
for human health. 
Done at Brussels, 19 December 1990. 
The Chairman 
of the 
Economic and Social Committee 
FranQois STAEDELI N 
The Secretary-General 
of the 
Economic and Social Committee 
and Consumer Affairs 
Jacques MOREAU 
35 OPINION 
of the Economic and Social Committee 
on the 
Proposal for a Council Regulation (EEC) concerning 
the creation of a supplementary protection certificate for medicinal products 
(COM(90) 101  final· SYN 255) 
37 On 3 May 1990, the Council decided to consult the Economic and Social Committee, under Article 
100a of the Treaty establishing the European Economic Community, on the 
Proposal  for  a  Council  Regulation  (EEC)  concerning  the  creation  of a 
supplementary protection certificate for medicinal products 
(COM(90)  101 final -SYN 255). 
The Section for Industry, Commerce, Crafts and Services, which was responsible for preparing the 
Committee's work on  the subject, adopted its Opinion on 9 January 1991. The  Rapporteur was 
Mr HILKENS. 
At its 283rd  Plenary Session (meeting of 30 January 1991), the Economic and Social Committee 
adopted the following Opinion by with 81  votes in favour and 5 abstentions. 
*  *  * 
Whilst essentially endorsing the Commission proposal and the greater protection for the European 
pharmaceuticals industry for which it provides, the Committee would make the following observations 
and suggestions. 
1.  Introduction 
1.1.  This proposal, which is based on Article 100a of the EEC Treaty, falls within the framework 
of a Community health policy or, more specifically, of an  internal market for medicinal 
products. 
1.2.  In assessing the draft, all the consequences of the proposed legislation must be taken into 
account. The pharmaceuticals sector and market exhibit certain peculiarities which affect 
both producers and consumers. 
1.3.  On the supply side, the need for extensive research makes patent protection necessary. 
Effective patent protection is, however, subject to gradual "erosion" owing to the numerous 
tests called for by the application dossier. On the demand side, medicinal products are of 
crucial importance for public health and therefore rate highly on the scale of consumer 
preferences, even though, at least in the case of prescription drugs, the decision to purchase 
does not rest with the consumer himself. 
1.4.  The Regulation is intended to ensure greater protection for innovation in the pharmaceu-
ticals sector. The best means of providing such protection is through patents. Although 
under the European Patent Convention which covers all products including pharmaceu-
ticals, patent protection is generally granted for 20 years in Europe, the numerous, obligatory 
(physio-chemical, biological or micro-biological, toxicological, pharmacological and clinical) 
tests reduce the exclusive exploitation period to only 8-12 years in the case of pharmaceu-
ticals. This situation is the result of administrative procedures which are recognized as 
necessary precautions for the marketing of medicinal products. Furthermore, the effect of 
brand loyalty over longer exploitation periods should not be underestimated in the case of 
many products. 
1.5.  In outlining the content and scope of its proposal, the Commission makes clear that the 
purpose of the draft Regulation is to restore the effective period of patent protection so as 
to encourage innovation in the Community's pharmaceuticals industry while at the same 
time avoiding discrimination visvis other industrial sectors. Another aim is to close the gap 
between the Community and the USA/Japan with regard to patent protection for basic 
innovations in the pharmaceuticals industry. 
39 2.  Broad outlines of the proposal for a Regulation 
2.1.  The proposal assumes that research is vital, both for the pharmaceuticals industry itself 
and for society as a whole. Accordingly, in Europe the industry allocates between 10 and 
15°/o  of its turnover for pharmaceuticals research on a self-financing basis. The patent 
protection system is therefore of crucial importance, since it makes it possible to recoup 
research investment during a period of exclusive exploitation, thereby securing the self-
financing process and guaranteeing future research. 
2.2.  Over the last ten years, the level of the European pharmaceuticals industry's research-
expressed as its share of the total number of molecules developed- has declined from 65°/o 
to 40°/o.  This situation could enable competitors, particularly in  the US  and Japan, to 
increase their market share further at Europe's expense. 
2.3.  The principal aims of the proposed Regulation relate to the efficient operation of the internal 
market, the improved competitiveness of Community industry and the promotion of research 
and development in the health field. 
2.4.  The proposed certificate will be issued by national patent offices at the request of the--holder 
of a national or European patent (the "basic" patent) in respect of a product authorized to 
be marketed in the country concerned.lt does not protect the expired patent in its entirety, 
but only the basic innovation which has also been authorized to be placed on the market. 
3.  General comments 
3.1.  The Committee recognizes that, in the interests of health protection, the marketing of 
medicinal products in the Community must be subject to stringent quality and therapeutic 
requirements. It therefore approves of the existing Community authorization procedures 
and  those still to be  introduced.  Patent  protection  for innovation  in  the Community 
pharmaceuticals industry can also be said to contribute to health protection. 
3.2.  Whilst the Committee is aware that the Single European Act states (in Declaration No.4) 
that the Commission should give precedence to the use of a Directive under Article 100a, 
it nevertheless believes that the Commission is correct in preferring the use of a Regulation 
in this instance and endorses the proposal. It is important that all Member States implement 
the extended period of a patent simultaneously: a Regulation can achieve this, but the 
legislation to enact the requirements of a Directive in each Member State can be of indeter-
minate duration. 
3.3.  The Committee thinks that the additional period of patent protection provided by the 
proposed certificate should also be looked at. 
A fair solution would be to align on US and Japanese patent protection laws so as to 
safeguard  the  competitive  position  of  the  Community's  pharmaceuticals  industry 
worldwide. 
3.4  The Committee calls on the Commission to examine all the economic consequences of the 
proposal, with particular reference to the duration of the protection certificate. 
3.4.1.  The interests of generics producers, who have an influence on price competition in a number 
of market segments, must also be borne in mind (generic medicinal products are pharmaceu-
ticals which contain the same chemically active principle as proprietary products-i.e. having 
chemical and therapeutic equivalence and the same bioavailability-and which are marketed 
after the proprietary products' protection has expired). In this connection, a balance must 
be  m~aintained between the interests of this industry and pharmaceuticals research. 
40 3A.2.  The Committee urges the Commission to verify whether the direct interests of generics 
producers will be damaged by the transitional provisions set out in Article  13(2) of the 
proposal. 
3.5.  The Committee thinks that consideration must also be given to the scope of the proposed 
Regulation. Thus, the concept of a "basic patent" used, inter alia, in Article 3 appears to 
bear no relation in most cases to the concept of a "basic innovation". Since, in its view, 
the Regulation should be restricted to pharmaceutical discoveries which genuinely involve 
a basic innovation, the Committee urges the Commission to lay down explicit criteria to 
this end. 
3.6.  The introduction of the supplementary protection certificate would seem likely to produce 
a sharp increase in the cost of, and expenditure on, medicinal products, particularly if the 
scope of the Regulation were to be broadly defined. This increased burden will be borne 
by  consumers  and  health-insurance schemes.  On  the  basis  of a  number of general 
conditions, the Commission  puts this overall  increase at 1  °/o  of the total turnover in 
medicinal products in the first year. The Committee calls on the Commission to take account 
of these factors and introduce appropriate measures to deal with them. 
3.7.  The Committee proposes that, after the Regulation has been in force for five years, the 
Commission should draw up an evaluation report on which the European Parliament and 
the Economic and Social Committee may comment. 
Done at Brussels, 30 january 1991. 
The Chairman 
of the 
Economic and Social Committee 
Fran<,;ois ST  AEDELI N 
The Secretary-General 
of the 
Economic and Social Committee 
Jacques MOREAU 
41 OPINION 
of the 
Economic and Social Committee 
on the 
Proposal for a Council Regulation (EEC) laying down 
Community procedures for the authorization and supervision 
of medicinal products for human and veterinary use 
and establishing a European Agency for the Evaluation of Medicinal Products 
Proposal for a Council Directive amending Directives 65/65/EEC, 
75/318/EEC and 75/319/EEC in respect of medicinal products 
Proposal for a Council Directive amending Directives 81/851/EEC 
and 81/852/EEC in respect of veterinary medicinal products 
Proposal for a Council Directive repealing Directive 87/22/EEC 
on the approximation of national measures relating to the placing 
on the market of high Otechnology medicinal products 
particularly those derived from biotechnology 
(COM(90) 283 final· SYN 309 to 312) 
43 On 3 December 1990, the Council decided to consult the Economic and Social Committee, under 
Article 100a of the Treaty establishing the European Economic Community, on the 
Proposal for a Council Regulation (EEC) laying down Community  procedures for 
the  authorization  and supervision  of medicinal products  for human  and 
veterinary use and establishing a  European  Agency for the  Evaluation of 
Medicinal Products 
Proposal for  a Council Directive amending Directives 65165/EEC, 751318/EEC and 
751319/EEC in respect of  medicinal products 
Proposal for a Council Directive amending Directives 811851/EEC and  811852/EEC 
in respect of veterinary medicinal products 
Proposal for a Council Directive repealing Directive 87122/EEC on the approxi-
mation of national measures relating to the placing on the market of high 
technology medicinal products particularly those derived from biotechnology 
(COM(90) 283 final- SYN 309 to 312) 
The Section for Protection of the Environment, Public Health and Consumer Affairs, which was 
responsible for preparing the Committee's work on the subject, adopted its Opinion on 4  June 1991. 
The Rapporteur was Mr COLOMBO. 
At its 288th Plenary Session (meeting of 4 July 1991), the Economic and Social Committee adopted 
the following Opinion unanimously: 
*  *  * 
1.  Preliminary comments 
1.1.  The Committee welcomes the Commission proposals, and in particular the proposal to set 
up a European Agency for the Evaluation of Medicinal Products; this marks the culminating 
point in the major package of measures to harmonize the market in medicinal products. 
1.2.  The importance of the Agency lies in the remit and role which will be assigned to lt. Alongside 
this remit -outlined below - the Agency will also act as guarantor for the implementing 
arrangements of the other Directives currently being adopted (wholesale distribution, legal 
status, labelling and advertising, patents), on most of which the Committee has already 
issued Opinions1. 
1.3.  These earlier proposals, although an undeniable step forward on the road to Community · 
harmonization, leave room for differing interpretations at national level of certain key points. 
1.4.  Any such differing interpretations would impede real free movement of medicinal products 
within the Community, which is necessary if consumers are to be guaranteed equal access 
to these products and there is to be equal protection of public health and safety. 
1.5.  In industrial terms, EC  legislation must safeguard and improve the competitiveness of 
Community products.  Their quality is  already  high,  and  can  be  further improved  by 
coordinating and boosting the fundamental role played by scientific research. 
1.6.  While we should endorse the aim of safeguarding and supporting the EC's pharmaceuticals 
industry by means of harmonized authorization procedures, account must also be taken 
of the social aspects of the pharmaceuticals sector, and the need to make procedures as 
transparent as possible. The experience gleaned by  Member States' health insurance 
systems can be of particular help here. 
OJ C 225 of 10 September 1990, OJ C 60 of 8 March 1991 and OJ C 69 of 18 March 1991. 
45 46 
1.7.  It is not enough simply to state that the interests of the consumer (and thus the needs of 
the patient who should be the prime beneficiary of the drug) are paramount; this intention 
must be given concrete legitimation by setting up a specific forum where these interests 
can be voiced. 
1.8.  Lastly, in the run-up to a People's Europe with free movement, the Community cannot shirk 
the question of  harmonization of drug pricing and reimbursement systems. The significant 
divergences which still persist in this field will appear increasingly unacceptable as the EC 
drug authorization system gets under way. The Committee notes that the Commission is 
working on this problem, and urges it to analyze the various systems and draw up proposals 
at an early opportunity. 
1.9.  The present proposals, examined in greater detail below, seem to reflect a cautious gradual 
approach which is nevertheless ambitious in intention. 
1.10.  The innovative features are tempered by a whole host of safeguard clauses placed at the 
disposal of the Member States. These clauses could seriously encumber the procedures 
and delay real free movement of medicinal products within the Community. 
1.11.  The recommendations which follow are designed to make the procedures more efficient 
and ensure a smooth transition to the new system. 
2.  Character, scale and duties of the Agency 
2.1.  The Agency has aroused the expectations and keen attention of the entire EC health and 
pharmaceuticals sectors. This in itself is an indication of the key role which the Agency 
is to play in this sensitive sector. 
2.2.  The  proposed  structure  will  mean  the  strengthening  of the  existing  Committee  for 
Proprietary  Medicinal  Products  and  Committee  for  Veterinary  Medicinal  Products 
(CPMP/CVMP). This strengthened role should lead to the creation of a structure guaranteeing 
independeflt assessment, balanced representation of experts from the Member States and 
of the various biological and medical "schools of thought" in the Community, and a multidis-
ciplinary scientific contribution. 
2.3.  The tasks of the Agency will be gradually extended during a transitional period under which 
national procedures are to remain in force until1996, alongside a centralized procedure for 
certain categories of drug, and the phasing-in of new EC procedures for the registration 
of medicinal products. 
2.4.  Initially, the Agency's main task will be to coordinate, assess and monitor the activity of 
the Member States. Only where disputes arise will the Agency be able to enforce a binding 
arbitration procedure. 
2.5.  However, the Agency will later assume wider responsibilities in the fields of public health 
protection and industrial policy with respect to medicinal products. 
2.6.  The Agency's main duties in the public health field will be to provide: 
- scientific EC-Ievel evaluation of authorization applications which require the centralized 
procedure or are brought to arbitration; 
- a guarantee that new medicinal products meet rigorous EC quality, safety and efficacy 
requirements; - better coordination of  the withdrawal or restriction of  drugs in the event of a serious threat 
to health; 
- identical published information valid throughout the Community (as requested by the 
Committee in its Opinion on labelling and package leaflets)2; 
- an ambitious commitment to bolster the Community's preclinical and clinical research 
facilities; 
-coordination of inspections and pharmacovigilance; 
-an assessment of the health hazards of residues of veterinary medicinal p·roducts in 
foodstuffs. 
2.7.  In the field of industrial policy, the Agency should offer valuable support for EC businesses 
by: 
-preparing EC Guidelines on the presentation and content of authorization applications, 
drawing on the experience already gained in this area; 
- 1aying down a standard, simple (in administrative and linguistic terms) format for appli-
cations; 
-observance of specified time-limits for the issue of marketing authorizations for new 
products; 
-protecting the applicant's confidentiality, thanks to the deposit of a single file; 
-offering the possibility of preliminary advice on the tests to be carried out; 
-enhancing the status of Community-produced medicines on export markets (authori-
zations will guarantee high therapeutic value). 
2.8.  The Agency is also to adopt simple, transparent procedures backed by objective assessment 
criteria to guarantee the applicant that data will be treated in confidence. The applicant 
will be allowed to appeal to the various responsible authorities if  the authorization is refused. 
2.9.  Lastly, the Agency is to tackle matters of particular Community interest, such as the pooling 
of expertise, harmonization of scientific evaluations and harmonized management of EC 
authorizations with a view to the Single Market. 
2.10.  As regards pharmacovigilance in particular, the Committee considers it vital for information 
to be as transparent and well-publicized as possible. Instruments should be set up for EC-
Ievel collection and rapid transmission of data. 
3.  Comments on the authorization procedures 
3.1.  Harmonization of the authorization procedures is the central feature of the package, and 
will form the linchpin of the future EC pharmaceuticals market. 
OJ C 225 of 10 September 1990, OJ C 60 of 8 March 1991 and OJ C 69 of 18 March 1991. 
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Account has to be taken of the fact that although EC-wide free movement of drugs brings 
a need for new regulations, the fragmented regulatory system which already exists cannot 
be dismantled overnight; it must be amended rationally and gradually. 
3.3.  Such a totally new system will require a transitional period whose duration is difficult to 
determine in advance. An overhasty transition could jeopardize the effectiveness of the new 
instruments. In  order to ensure that the process goes smoothly and  to facilitate the 
completion of the new structures, existing instruments should be retained during the transi-
tional period until the new EC instruments have got through any teething troubles. 
3.4.  At all events, in the interests of the consumer, the procedures must obviously all meet 
rigorous quality, efficacy and safety criteria. 
3.5.  The national procedure 
3.5.1.  Continued use of national procedures is justified, as it offers a guarantee for smaller firms 
producing drugs solely for the domestic market who do not wish their authorization to be 
extended to other Member States. 
3.5.2.  Moreover, the national procedure will form the basis for the decentralized EC procedure 
discussed below. 
3.6.  Decentralized EC procedure 
3.6.1.  As the "multi-state" procedure has failed in practice because it has been very unevenly 
applied by the Member States, the Commission has devised two complementary procedures 
for regulating free movement of drugs within the Community. 
3.6.2.  The decentralized procedure is based on mutual recognition, whereby authorization in one 
Member State is subsequently extended to other States. Under this procedure the decision-
taking powers of the Member States remain virtually unchanged, although the Agency 
acquires the role of arbiter. 
3.6.3.  This is a step forward from the "multi-state" procedure, as it establishes clearer time-limits 
and allows firms to decide for themselves how many further authorizations to request. 
3.6.4.  The procedure offers a gradual move to the European market for firms which wish to reach 
this wider market. 
3.6.5.  However, the procedure is less advantageous for the patient/consumer, as it could mean 
that new drugs take longer to reach the market, and does not guarantee their availability 
in all Member States. 
3.6.6.  Furthermore, recourse to the Agency's arbitration should not become the standard practice. 
Its rulings should be binding in all Member States and not, as presently envisaged, simply 
in the Member State opposing the application. This would prevent needless proliferation 
of applications to the Agency by the Member States. 
3.6.7.  Lastly, Member States must be prevented from opposing applications on any grounds other 
than efficacy, quality and safety. This is important in order to avoid disguised forms of 
protectionism which would impede the establishment of a real Single Market. 
3. 7.  The centralized procedure 
3.7.1.  The second procedure is a centralized one leading to an authorization which is immediately 
valid in all Member States. Decision-taking power is concentrated in the European Drugs 
Agency. 
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for direct human use, the centralized procedure is: 
- obligatory only for products developed by means of certain biotechnological processes; 
- optional for those developed by means of other biotechnological processes, or by means 
of highly technological and innovative processes. 
3.7.3.  The Committee wonders whether this distinction properly protects the interests of either 
the "passive consumer" (i.e. the patient) or the "active consumer" (the doctor who prescribes 
the drug and is thus the real promoter of its consumption). 
3.7.4.  Moreover, there are some fields of pathology in which there is always a need for effective, 
highly innovative drugs. Anti-cancer drugs are not the only important example where gradual 
introduction of the centralized procedure would appear warranted. 
3.7.5.  The procedure should however remain  optional for these categories of drug, and  the 
bureaucratic procedures should be simplified, while rigidly adhering to the criteria laid down. 
3.7.6.  Drugs subject to this procedure will naturally enjoy a high "scientific status" and prestigious 
label, which will also help them in markets outside the EC. 
3.7.7.  The centralized procedure would also have three practical advantages: 
-all  EC patients would have immediate access to the above-mentioned innovative drugs, 
without having to experience the lengthy delays which the authorization procedure in 
the individual Member States would inevitably entail; 
-it  would make the best possible use of specialist skills, preventing twelve groups of 
people  from  having  to  examine  substances  which  could  be  examined  perfectly 
thoroughly by one single (and thus larger) group of experts of high and unquestionable 
international standing; 
- there would be an a priori guarantee that, because industry's preclinical and clinical 
research had to meet more rigorous standards, manufacturers would only put forward 
drugs of a fully proven innovative nature in technical and/or medical and biological terms. 
3.7.8.  The Committee therefore asks the Commission to consider the case for gradually extending 
optional use of the centralized procedure to other categories of drug. 
3.8.  Veterinary medicinal products 
3.8.1.  The above criteria also apply to the authorization of veterinary medicinal products. However, 
greater centralization might be desirable in the case of medicinal products for animals 
intended for human consumption, in view of the Community interests at stake (residues, 
movement of food products, etc.). For drugs administered to domestic pets such as cats 
and dogs, on the other hand, the aim should be automatic mutual recognition without 
recourse to central arbitration.  · 
3.8.2.  The Committee views with concern the reference to the CAP in connection with the authori-
zation of veterinary medicinal products (fourth recital of the Regulation establishing the 
Agency). The Agency is concerned with the quality, safety and efficacy of drugs, and does 
not seem the appropriate place for political and economic judgments. Its remit should be 
confined to public health considerations. 
4.  Structure and scientific quality 
4.1.  The key role which the Agency is to play in the assessment process means that it must be 
completely neutral and independent, and that its monitoring functions must be multidis-
ciplinary. The Agency's technical and scientific structure must provide balanced represen-
tation of experts from the various Member States, and the different disciplines must be fully 
represented on the assessment committees. 
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4.2.  The Committee endorses the Commission's decision to set up a light central structure, 
relying  heavily  on  national  experts  operating  in  their regular  places  of activity. The 
Committee also appreciates the intention (Articles 50 to 52) to ensure the scientific indepen-
dence of the Agency and the impartiality of its experts, and to avoid interference from 
industry and intervention by the national authorities which would be incompatible with 
assessment duties. 
4.3.  The establishment of a European college of experts based on national lists endorsed and 
updated by the Member States, as laid down in Article 51, appears vital. These lists, which 
should be made public, should mention the experts' academic and technical qualifications, 
along  with  details of their  research  work and  publications,  and  should  include the 
declaration of other interests mentioned in Article 52. 
4.3.  If the centralized procedure proves its worth as a swift and competent system, the number 
of central staff could gradually be increased by recruitment from national bodies. 
Done at Brussels, 4 July 1991. 
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